139 related articles for article (PubMed ID: 15354013)
1. Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas.
O'Reilly BF; Kishore A; Crowther JA; Smith C
Otol Neurotol; 2004 Sep; 25(5):791-6. PubMed ID: 15354013
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of transforming growth factor-beta1 and glial cell line-derived neurotrophic factor in vestibular schwannoma.
Diensthuber M; Brandis A; Lenarz T; Stöver T
Otol Neurotol; 2004 May; 25(3):359-65. PubMed ID: 15129118
[TBL] [Abstract][Full Text] [Related]
3. Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: possible autocrine loop stimulation.
Hansen MR; Linthicum FH
Otol Neurotol; 2004 Mar; 25(2):155-9. PubMed ID: 15021776
[TBL] [Abstract][Full Text] [Related]
4. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
[TBL] [Abstract][Full Text] [Related]
6. Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation.
Torres-Martin M; Lassaletta L; San-Roman-Montero J; De Campos JM; Isla A; Gavilan J; Melendez B; Pinto GR; Burbano RR; Castresana JS; Rey JA
Int J Oncol; 2013 Mar; 42(3):848-62. PubMed ID: 23354516
[TBL] [Abstract][Full Text] [Related]
7. Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma.
Dillard DG; Venkatraman G; Cohen C; Delgaudio J; Gal AA; Mattox DE
Acta Otolaryngol; 2001 Jan; 121(2):149-52. PubMed ID: 11349767
[TBL] [Abstract][Full Text] [Related]
8. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
[TBL] [Abstract][Full Text] [Related]
9. Vestibular schwannoma: role of conservative management.
Suryanarayanan R; Ramsden RT; Saeed SR; Aggarwal R; King AT; Rutherford SA; Evans DG; Gillespie JE
J Laryngol Otol; 2010 Mar; 124(3):251-7. PubMed ID: 20003606
[TBL] [Abstract][Full Text] [Related]
10. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
[TBL] [Abstract][Full Text] [Related]
11. Atypical and low-grade malignant vestibular schwannomas: clinical implications of proliferative activity.
Light JP; Roland JT; Fishman A; Miller DC; Cohen NL
Otol Neurotol; 2001 Nov; 22(6):922-7. PubMed ID: 11698820
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate.
Cayé-Thomasen P; Baandrup L; Jacobsen GK; Thomsen J; Stangerup SE
Laryngoscope; 2003 Dec; 113(12):2129-34. PubMed ID: 14660915
[TBL] [Abstract][Full Text] [Related]
13. The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1.
Aguiar PH; Tatagiba M; Samii M; Dankoweit-Timpe E; Ostertag H
Acta Neurochir (Wien); 1995; 134(1-2):40-5. PubMed ID: 7668124
[TBL] [Abstract][Full Text] [Related]
14. cDNA microarray analysis of vestibular schwannomas.
Welling DB; Lasak JM; Akhmametyeva E; Ghaheri B; Chang LS
Otol Neurotol; 2002 Sep; 23(5):736-48. PubMed ID: 12218628
[TBL] [Abstract][Full Text] [Related]
15. Expression of ErbB-1 and 2 in vestibular schwannomas.
Wickremesekera A; Hovens CM; Kaye AH
J Clin Neurosci; 2007 Dec; 14(12):1199-206. PubMed ID: 17964790
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics.
Koutsimpelas D; Stripf T; Heinrich UR; Mann WJ; Brieger J
Otol Neurotol; 2007 Dec; 28(8):1094-9. PubMed ID: 17721409
[TBL] [Abstract][Full Text] [Related]
17. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Imaging in the Diagnosis and Management of Patients With Vestibular Schwannomas.
Dunn IF; Bi WL; Mukundan S; Delman BN; Parish J; Atkins T; Asher AL; Olson JJ
Neurosurgery; 2018 Feb; 82(2):E32-E34. PubMed ID: 29309686
[TBL] [Abstract][Full Text] [Related]
18. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas.
Caltabiano R; Magro G; Polizzi A; Praticò AD; Ortensi A; D'Orazi V; Panunzi A; Milone P; Maiolino L; Nicita F; Capone GL; Sestini R; Paganini I; Muglia M; Cavallaro S; Lanzafame S; Papi L; Ruggieri M
Childs Nerv Syst; 2017 Jun; 33(6):933-940. PubMed ID: 28365909
[TBL] [Abstract][Full Text] [Related]
19. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.
Slattery WH; Fisher LM; Iqbal Z; Oppenhiemer M
Otol Neurotol; 2004 Sep; 25(5):811-7. PubMed ID: 15354016
[TBL] [Abstract][Full Text] [Related]
20. [Neurotrophic factor expression in vestibular schwannoma. An overview].
Diensthuber M; Lenarz T; Stöver T
Laryngorhinootologie; 2006 Oct; 85(10):731-7. PubMed ID: 16612755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
